There’s no data from a head-to-head trial directly comparing Eli Lilly and Novo Nordisk’s GLP-1 agonist drugs yet, but an observational study has found that Lilly’s tirzepatide seems to be
Scotland has become the first country in the UK to back NHS use of Eli Lilly’s obesity therapy Mounjaro, clearing it to assist weight management in eligible patients.
Eli Lilly is determined not to be left behind when it comes to manufacturing capacity for new diabetes and obesity therapies, raising its spending on a new plant in Indian
Eli Lilly is just weeks away from launching Mounjaro in the UK, after getting approval from medicines regulator, the MHRA, for a new formulation of the drug as a treatment
Eli Lilly has followed Novo Nordisk in announcing a big investment in its manufacturing network, intended to meet anticipated strong future demand for diabetes and obesity
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh